论文部分内容阅读
目的探讨外周血与肿瘤组织中核苷酸还原酶M1(ribonucleotide reductase M1,RRM1)表达的相关性,并进一步分析其与吉西他滨联合铂类治疗非小细胞肺癌(non-small-cell lung cancer,NSCLC)预后的相关意义。方法通过荧光实时定量PCR检测34例NSCLC患者外周血中RRM1 mRNA表达水平,并与患者的组织病理学类型、临床分期及吉西他滨联合铂类化疗方案疗效的关系进行分析。同时进一步对外周血和肿瘤组织中RRM1 mRNA表达水平的相关性进行分析研究。结果外周血中的RRM1 mRNA在不同的临床分期(ⅢB和Ⅳ)和组织病理学类型(鳞癌、腺癌)中表达均无差异;在与肿瘤化疗反应相关性分析中发现,RRM1低表达组有效率(52.9%)、高于高表达组(5.9%)(P<0.05)。同时,在对生存期的分析中发现RRM1低表达组的生存期(15.5月)明显长于高表达组(11.8月)(P<0.05)。且外周血中RRM1 mRNA的表达与肿瘤组织中呈线性相关(P=0.004)。结论外周血中RRM1低表达的NSCLC患者对吉西他滨化疗反应的有效率更高,生存期更长,其将有助于遴选适合接受吉西他滨联合铂类一线化疗方案的患者。
Objective To investigate the correlation between peripheral blood and the expression of ribonucleoprotein reductase M1 (RRM1) in peripheral blood and tumor tissues, and to further analyze its relationship with gemcitabine and platinum in the treatment of non-small-cell lung cancer (NSCLC) Relevance of prognosis. Methods The expression of RRM1 mRNA in peripheral blood of 34 patients with NSCLC was detected by real-time fluorescence quantitative PCR. The relationship between the expression of RRM1 mRNA and the histopathological type, clinical stage and efficacy of gemcitabine combined with platinum-based chemotherapy was analyzed. At the same time, the correlation between RRM1 mRNA expression level in peripheral blood and tumor tissue was further analyzed. Results There was no difference in the expression of RRM1 mRNA in peripheral blood between different clinical stages (ⅢB and Ⅳ) and histopathological types (squamous cell carcinoma and adenocarcinoma). Correlation analysis showed that RRM1 low expression group Efficacy (52.9%), higher than the high expression group (5.9%) (P <0.05). At the same time, in survival analysis, the survival of RRM1 low expression group (15.5 months) was significantly longer than that of high expression group (11.8 months) (P <0.05). The expression of RRM1 mRNA in peripheral blood was linearly correlated with tumor tissue (P = 0.004). Conclusions NSCLC patients with low expression of RRM1 in peripheral blood are more efficient and longer-lived in the response to gemcitabine chemotherapy, which will be helpful for the selection of patients who are eligible for gemcitabine plus platinum first-line chemotherapy.